ArticleBlood2013
Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity.
Article in Blood, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis.Clinical lymphoma, myeloma & leukemia · 2020Pooled it
- Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.JAMA oncology · 2017Pooled it
- Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.Cytometry. Part B, Clinical cytometry · 2016Guideline
- Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study.Haematologica · 2016Trial
- Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.JAMA oncology · 2015Trial
- Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.Blood · 2014Trial
- Applications of Multiparameter Flow Cytometry in the Diagnosis, Prognosis, and Monitoring of Multiple Myeloma Patients.Diseases (Basel, Switzerland) · 2025Review
- Review
- Review
- Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis.Cytometry. Part B, Clinical cytometry · 2022Article
- Harmonization of Flow Cytometric Minimal Residual Disease Assessment in Multiple Myeloma in Centers of Polish Myeloma Consortium.Diagnostics (Basel, Switzerland) · 2021Article
- Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.Blood reviews · 2021Review
- Standardization of flow cytometric minimal residual disease assessment in international clinical trials - a feasibility study from the European Myeloma Network.Haematologica · 2020Article
- Discovery and validation of surfaceJournal for immunotherapy of cancer · 2020Article
- Characterization of circulating myeloma tumor cells by next generation flowcytometry in scleromyxedema patient: a case report.Medicine · 2020Article
- Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma.Bone marrow transplantation · 2020Article
- Clinical value of measurable residual disease testing for multiple myeloma and implementation in Japan.International journal of hematology · 2020Review
- Delaying the use of high-dose melphalan with stem cell rescue in multiple myeloma is ready for prime time.Clinical advances in hematology & oncology : H&O · 2019Review
- Flow Cytometric Evaluation of Traditional and Novel Surface Markers for the Diagnosis of Plasma Cell Dyscrasias.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2019Article
- Monitoring of Measurable Residual Disease in Multiple Myeloma by Multiparametric Flow Cytometry.Current protocols in cytometry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.